UPDATE 1-Avalanche eye therapy meets safety goal; vision improvement modest
June 15, 2015 at 17:27 PM EDT
June 15 (Reuters) - Avalanche Biotechnologies Inc's experimental gene therapy for a leading cause of blindness met its primary safety goal in a small mid-stage trial, while staving off vision loss.
